TORONTO, Jan. 11 /PRNewswire-FirstCall/ -- MedCap Corp (Pinksheets: MPCPF) is pleased to announce that it has begun negotiations to increase the line of AccuScan rapid test kits by adding rapid test kits for the detection of sexually transmitted diseases (STDs). The Company feels that adding the test kits for STDs will complement the demand for the kits related to the Drugs of Abuse.
The combination of rapid test kits for Drugs of Abuse and STDs will give the Company a comprehensive line of test kits. The demand for rapid test kits for STDs and Drugs of Abuse that are accurate, fast, inexpensive and can be used in the privacy of your own home is virtually unlimited.
In the United States alone there are 15 million new cases of STDs each year. At least one in four Americans will contract an STD at some point in their lives. Two thirds of all STDs occur in people 25 years of age or younger. One in four new STD infections occur in teenagers. Less than half of the adults ages 18 to 44 have ever been tested for an STD other than HIV/AIDS .
Market studies show that the combination of test kits for Drugs of Abuse and STDs is a good product line for our distribution network. As our distribution network gets established it is reasonable to expect that the Company will sell in excess of 3,000,000 test kits per year.
MedCap Corp trades in the United States on the Pinksheets under the symbol "MPCPF". For further information, please contact Cazgeld Capital Corporation at (416) 363 0070 or at http://www.medccorp.com/.
NOTE: This release may contain forward-looking statements that involve uncertainties and risks. Actual results may differ materially from any results predicted. MedCap undertakes no obligation to release publicly any revision to any forward-looking statements to reflect events of circumstances after the date hereof.
CONTACT: Cazgeld Capital Corporation for MedCap Corp, +1-416-363 0070